Abstract
The approval of the first direct-acting antivirals (DAAs) against the hepatitis C virus (HCV) has been eagerly expected for treating chronic hepatitis C in HIV individuals given that progression to cirrhosis and end-stage liver disease occurs faster in the co-infected population. The appropriate and judicious use of DAAs may provide cure to a large number of HIV-HCV patients. On the contrary, the widespread use of DAAs will occasionally be off-label or under unsatisfactory medical conditions, which may result in undesirable toxicities, drug interactions or selection of drug resistance in HCV. As a result of using first-generation DAAs in HIV-HCV-co-infected patients, a growing proportion of the remaining hepatitis C individuals will be those harboring non-HCV 1 genotypes or drug-resistant HCV variants. Over time, the largest reservoir of HCV genotype 1 patients will accumulate in resource-poor nations where access to hepatitis C therapy has been elusive and HIV treatment remains the primary health issue for the co-infected population.
Original language | English |
---|---|
Pages (from-to) | 2197-2208 |
Number of pages | 12 |
Journal | AIDS |
Volume | 25 |
Issue number | 18 |
DOIs | |
State | Published - 28 Nov 2011 |
Keywords
- HIV
- boceprevir
- co-infection
- direct-acting antivirals
- drug resistance
- hepatitis C
- liver
- telaprevir